PLUSTM

CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment helps in clinical management of breast cancer and Non-Small Cell Lung cancer patients having Leptomeningeal Disease (FORESEE Study, NCT05414123)

Priya Kumthekar, MD

Associate Professor of Neurology and Hematology/Oncology Director, Brain Metastases Program Northwestern University August 2024





Summary

FORESEE was a clinical utility study assessing the impact of the CSF diagnostic platform CNSide on disease management of patients with Leptomeningeal Disease

Preliminary analysis shows that CNSide:


- + Contributed to making a clinical decision in 91% (50/55) of decisions
- + Confirmed a positive LM diagnosis on 18% (7/39) of patients
- + Confirmed a negative LM diagnosis in 8% (3/39) of patients
- + Informed a specific drug selection in 26% (10/39) patients

*Immature data






PLUS[°]



CNSide CSF Diagnostic Platform





Retrospective analyses showing utility

(but no prospective study to date)

No prospective data in controlled setting to confirm clinical utility observed from retrospective analysis **Need to understand** clinical performance of tumor cell detection of CNSide compared to current gold standard, CSF cytology


CNSide helps to diagnose LMD

CNSide helps to determine response to LMD directed therapy CNSide helps to inform specific LMD therapy selection



FORESEE Study:

Trial Schema



- + At each visit, CNSide's contribution to a clinical decision was evaluated via a Questionnaire
- + Treatment decisions were at Physician discretion
- + Enrollment goal: 20 patients with breast cancer, 20 with NSCLC





₽LUS[®]





Primary End Point

Evaluate if CNSide contributes to a clinical decision (Target: 20% of decisions)

Secondary End Point

Evaluate tumor cell detection by CNSide as a therapy response monitoring tool Sensitivity, Specificity, NPV and PPV of CNSide compared to CSF cytology





FORESEE Study: Inclusion and Exclusion criteria



Inclusion Criteria

- + Positive breast cancer or NSCLC diagnosis
- + Suspected or confirmed LMD diagnosis
- + Willingness to sign informed consent
- + Positive or negative for Parenchymal brain metastasis

Exclusion criteria

- + Patients with any other cancer than breast cancer or NSCLC cancer
- + Patients with a primary brain tumor

Title	NCT#	Primary End Point	Type of Test
BESPOKE Study of ctDNA Guided Immunotherapy	04761783	Percent of Melanoma, - NSCLC and Colorectal patients who have their immunotherapy treatment regimen changed due to the SIGNATERA ctDNA test result	Patient tailored gene panel to detect cfDNA from the blood
Treatment Decision Impact of OncotypeDx in HR+, N- Breast Cancer Patients (SWITCH)	01446185	Impact of OncotypeDx Recurrent Score on treatment decisions	21-gene test that predicts recurrence of early-stage breast cancer
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer	02825875	Changes to clinical management of patients with prostate cancer after Physician reviews a PET/CT scan of PSMA	PSMA Imaging by PET/CT
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions after Surgery (PRO-IMPACT)	02080689	Number of participants for which the Urologist changed the patient's treatment plan based on Decipher test results	Next Generation Sequencing of tumor tissue
Decision Impact Study of PreciseDx Breast (PDxBRUTILITY)	06309615	Proportion of Physicians who utilized PBxBR results in their management of patients with invasive breast cancer (target: 20%)	Combination of Artificial Intelligent grading of histology and clinical data that predicts recurrence in early- stage breast cancer patients

FORESEE Study:

Physician Questionnaire

PLUS

Baseline:

- + Was the patient diagnosed with LM prior to Baseline visit (yes, no)
 - + If no, is the patient diagnosed with LM at the Baseline visit (yes, no)
 - + If yes, what is the status of the LM tumor at this visit (No Change, Progression, Resolution)
- + Did CNSide contribute to this assessment? (yes, no)
- + Did CNSide inform the specific drug selected for treatment? (yes, no)

Subsequent visits:

- + What is the status of the LM tumor (No Change, Progression, Resolution)
- + Did CNSide contribute to this assessment? (yes, no)
- + Did CNSide inform the specific drug selected for treatment? (yes, no)


Patient Demographics

	Breast Cancer (N=21)	NSCLC (N=18)
Age range	58 years	58 years
Gender	F (N=21)	F (N=9), M (N=9)
Parenchymal brain metastasis diagnosed prior to enrollment	52% (11/21) Positive, 43% (9/21) Negative , 5% (1/21) Unknown	56% (10/18) Positive, 44% (8/18)) Negative
LMD Diagnosed prior to trial enrollment (by investigator assessment)	81% (17/21) Positive, 14% (3/21) Negative, 5% (1/21) Unknown	61% (11/18) Positive, 39% (7/18) Negative
Primary HER2 status	19% (4/21) Positive, 76% (16/21) Negative, 5% (1/21) Unknown	Not Applicable
Primary HER2-/ER-/PR-	9% (2/21)	Not Applicable
Primary ER+	76% (16/21) Positive, 19% (4/21) Negative, 5% (1/21) Unknown	Not Applicable
Primary PR+	67% (14/21) Positive, 24% (5/21) Negative, 10% (2/21) Unknown	Not Applicable
Number of Questionnaires completed (N=55 total; 29 BC and 26 NSCLC)	72% (21/29) Baseline, 24% (7/29) First Visit, 3% (1/29) Second Visit	69% (18/26) Baseline, 33% (6/26) First Visit, 8% (2/26) Second Visit
Number of patients with Baseline Visit	21	18
Number of patients with Baseline + First Visit	7	6
Number of patients with Baseline + First Visit + Second Visit	1	2



Take Home #1:

CNSide helped make clinical decisions in LMD patients









Take Home #2:

CNSide helped to diagnose LMD

N=10 patients not diagnosed with LMD prior to trial enrollment

+ These patients were deemed LMD positive or negative after the Baseline visit based on Investigator assessment

LMD Positive Patients (N=7)

- + Cytology Positive, CNSide Positive: N=2
- + Cytology Negative, CNSide Positive: N=5


LMD Negative Patients (N=3)

- + All three patients were Cytology Negative and CNSide Negative
- + Investigators noted on the questionnaire that CNSide helped to rule out LMD

Take Home #3:




CNSide helped to evaluate the status of the LMD tumor (45 questionnaires)*



Take Home #4:

CNSide identified mutations used to make a specific drug selection









Improved sensitivity of tumor cell detection in LMD patients*with CNSide vs cytology** in matched samples

Cytology		LMD Status		
		Positive	Negative	Total
Cytology (positive or negative)	Positive	13	0	13
	Negative	27	3	30
	Total	40	3	43

Cytology

- + Sensitivity: 33%
- + Specificity: 100%
- + PPV: 100%
- + NPV: 10%

CNSide			LMD Status		
		Positive	Negative	Total	
CNSide (positive or negative)	Positive	31	0	31	
	Negative	9	3	12	
	Total	40	3	43	

CNSide

- + Sensitivity: 78%
- + Specificity: 100%
- + PPV: 100%
- + NPV: 25%

*LMD based on investigator assessment

** Only cytology Positive and Negative results included

₽LUS[™]

Improved sensitivity of tumor cell detection in LMD patients* of CNSide compared to cytology

Matched CSF samples (N=45, of N=39 unique patients) Patients with an LMD positive diagnosis (all visits)

- + Cytology detected cells in 29% (13/45) samples
- + Cytology did not detect cells in 60% (27/45) samples
- + Cytology was Atypical in 9% (4/45) samples
- + Cytology was Suspicious in 2% (1/45) samples

CNSide detected cells in 80% (36/45) samples CNSide did not detect cells in 20% (9/45) samples

Improved tumor cell detection in LMD patients* of CNSide compared to Cytology** in matched samples (N=45)

CNSide	Cytology		
 + Detected cells in 80% (36/45) samples of LMD Positive Patients (N=36) + Did not detect cells in LMD Negative Patients (N=3) 	 + Detected cells in 29% (13/45) samples of LMD Positive Patients (N=36) + Detected Atypical or Suspicious cells in (4/45) samples of LMD Positive Patients + Did not detect cells in LMD Negative Patients (N=3) 		

₽LUS[®]



Conclusions and Next Steps

Preliminary Conclusions

- + FORESEE study met primary end point
- + CNSide helped to make a clinical decision in 91% (50/55) of decisions
- + CNSide helped to inform therapy selection in 24% (13/55) of decisions
- + Compared to cytology in matched samples, CNSide more than doubled the sensitivity of tumor cell detection in the CSF

Next steps

+ Working with the sites to obtain mature data to be presented/published in near future

Acknowledgements

- + All patients who were enrolled in FORESEE trial
- + Investigators: Drs. Seema Nagpal, Jonathan Yang, Michael Youssef
- + Consultants: Dr. Laura Gillis, Dr. Kelly Gordon
- + Steering committee: Drs. Seema Nagpal, Priya Kumthekar, Michael Glantz, Santosh Kesari and David Berz
- + ICON
- + Dr. Barbara Blouw, Dr. David Isley
- + Biocept
- + Plus Therapeutics (Dr. Melissa Moore, Dr. Norman LaFrance, Dr. Marc Hedrick)









